Bevacizumab treatment of prostate cancer

Bibliography

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Kolata G. Hope in the lab: a special report; a cautious awe greets drugs that eradicate tumors in mice [Internet]. The New York Times; New York: NY 1998
   Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-70
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25
   PubMed Web of Science ®Google Scholar
• Ferrer FA, Miller LJ, Andrawis RI, Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329-33
   PubMed Web of Science ®Google Scholar
• Pallares J, Rojo F, Iriarte J, Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 2006;21:857-65
   PubMed Web of Science ®Google Scholar
• Gustavsson H, Welen K, Damber J-E. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005;62:364-73
   PubMed Web of Science ®Google Scholar
• Cox MC, Permenter M, Figg WD. Angiogenesis and prostate cancer: important laboratory and clinical findings. Curr Oncol Rep 2005;7:215-19
   PubMedGoogle Scholar
• Duque JL, Loughlin KR, Adam RM, Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523-7
   PubMed Web of Science ®Google Scholar
• Bok RA, Halabi S, Fei DT, Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001;61:2533-6
   PubMed Web of Science ®Google Scholar
• George DJ, Halabi S, Shepard TF, Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7:1932-6
   PubMed Web of Science ®Google Scholar
• Shariat SF, Anwuri VA, Lamb DJ, Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004;22:1655-63
   PubMed Web of Science ®Google Scholar
• Borre M, Offersen BV, Nerstrøm B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940-4
   PubMed Web of Science ®Google Scholar
• Borre M, Bentzen SM, Nerstrøm B, Overgaard J. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 1998;159:1609-14
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Wheeler TM, Blute M, Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996;48:47-57
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Carducci MA. Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets 2012;16(4):365-76
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O'Connor SJ, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9
   PubMed Web of Science ®Google Scholar
• Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999;161:960-3
   PubMed Web of Science ®Google Scholar
• Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-56
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Miller KD, Sissons SE, The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72
   PubMed Web of Science ®Google Scholar
• Gerber H-P, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50
   PubMed Web of Science ®Google Scholar
• Reese DM, Fratesi P, Corry M, A Phase II Trial of Humanized Anti-Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen-Independent Prostate Cancer. Prostate J 2001;3:65-70
   Google Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Figg WD, Fossa SD, Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54:1089-96
   PubMed Web of Science ®Google Scholar
• Francini F, Pascucci A, Francini E, Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. Prostate Cancer 2011;2011:258689
   PubMedGoogle Scholar
• Ning YM, Gulley JL, Arlen PM, Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070-6
   PubMed Web of Science ®Google Scholar
• Adesunloye B, Huang X, Ning Y, Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012;30(Suppl):abstract 207
   Google Scholar
• Picus J, Halabi S, Kelly WK, A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from cancer and leukemia group B study 90006. Cancer 2011;117:526-33
   PubMed Web of Science ®Google Scholar
• Savarese DM, Halabi S, Hars V, Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. cancer and leukemia group B. J Clin Oncol 2001;19:2509-16
   PubMed Web of Science ®Google Scholar
• Kelly WK, Halabi S, Carducci M, Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30(13):1534-40
   PubMed Web of Science ®Google Scholar
• Rini BI, Weinberg V, Fong L, Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006;107:67-74
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ishida T, Nadaf S, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963-70
   PubMed Web of Science ®Google Scholar
• Vuky J, Pham HT, Warren S, Phase II Study of Long-Term Androgen Suppression With Bevacizumab and Intensity-Modulated Radiation Therapy (IMRT) in High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2012;82:e609-15
   PubMed Web of Science ®Google Scholar
• Ross RW, Galsky MD, Febbo P, Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: A prostate cancer clinical trials consortium trial. Cancer 2012 Jan 26; doi: 10.1002/cncr.27416. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Febbo PG. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233-40
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R, Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-85
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Ning Y-M, Chen CC, Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009;27:221-6
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Badgwell BD, Camp ER, Feig B, Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008;19:577-82
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Dickler M. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47
   PubMed Web of Science ®Google Scholar
• Robert NJ, Dieras V, Glaspy J, Ribbon-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60
   PubMed Web of Science ®Google Scholar
• Hamburg MA. Proposal to withdraw approval for the breast cancer indication of avastin (bevacizumab) [Internet]. FDA.gov; Silver Spring: MD 2011
   Google Scholar
• Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15:4589-99
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Madan RA, Dahut WL. Angiogenesis inhibition in prostate cancer: current uses and future promises. J Oncol 2010;2010:361836
   PubMedGoogle Scholar
• Shojaei F, Lee JH, Simmons BH, HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010;70:10090-100
   PubMed Web of Science ®Google Scholar
• Aftab DT, McDonald DM. MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol 2011;13:703-9
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308
   PubMed Web of Science ®Google Scholar
• Hussain M, Smith M, Sweeney C, Corn P. Cabozantinib (XL184) in metastatic castration resistant prostate cancer (mCRPC): results from a Phase 2 randomized discontinuation trial. J Clin Oncol 2011;29(Suppl):abstract 4516
   Google Scholar